EDGAR Filing Documents for 0001144204-13-022773

Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]

SEC Accession No. 0001144204-13-022773

Filing Date

2013-04-19

Accepted

2013-04-18 18:09:11

Documents

Period of Report

2012-12-31

Interactive Data

Document Format Files

Seq	Description	Document	Type	Size
1	AMENDMENT NO. 1 TO 20-F	v338989_20fa1.htm	20-F/A	63039
	Complete submission text file	0001144204-13-022773.txt		5705786

Data Files

Seq	Description	Document	Type	Size
2	XBRL INSTANCE DOCUMENT	mrrby-20121231.xml	EX-101.INS	906951
3	XBRL TAXONOMY EXTENSION SCHEMA	mrrby-20121231.xsd	EX-101.SCH	64463
4	XBRL TAXONOMY EXTENSION CALCULATION LINKBASE	mrrby-20121231_cal.xml	EX-101.CAL	27621
5	XBRL TAXONOMY EXTENSION DEFINITION LINKBASE	mrrby-20121231_def.xml	EX-101.DEF	257288
6	XBRL TAXONOMY EXTENSION LABEL LINKBASE	mrrby-20121231_lab.xml	EX-101.LAB	396326
7	XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE	mrrby-20121231_pre.xml	EX-101.PRE	320986

Mailing Address C/O MARK COHEN, CHAIRMAN, PEARL COHEN 1500 BROADWAY, 12TH FLOOR NEW YORK NY 10036

Business Address 53 DAVIES STREET LONDON X0 W1K 5JH 646-878-0804

Morria Biopharmaceuticals PLC (Filer) CIK: 0001541157 (see all company filings)

IRS No.: 981034922 | State of Incorp.: X0
Type: 20-F/A | Act: 34 | File No.: 000-54749 | Film No.: 13770056
SIC: 2834 Pharmaceutical Preparations